Vinorelbine as first-line chemotherapy for metastatic breast carcinoma.

Romero, A; Rabinovich, M; Vallejo, Carlos; Pérez, J. Eduardo; Rodríguez, Ricardo; Cuevas, M A; Machiavelli, M; Lacava, J.; Langhi, M.; Acuña, L

doi:10.1200/jco.1994.12.2.336

Cited by 179 publications

(61 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…vinorelbine has been widely investigated in the treatment of MBC. Response rates of 35 -50% have consistently been demonstrated for first-line single-agent vinorelbine (Fumoleau et al, 1993;Garcia-Conde et al, 1994;Romero et al, 1994;Twelves et al, 1994;Bruno et al, 1995;Weber et al, 1995;Terenziani et al, 1996). The good tolerance profile of i.v.…”

mentioning

confidence: 92%

Vinorelbine alternating oral and intravenous plus epirubicin in first-line therapy of metastatic breast cancer: results of a multicentre phase II study

Serin

Verrill²,

Jones

et al. 2005

Br J Cancer

View full text Add to dashboard Cite

The combination of intravenous (i.v.) vinorelbine and epirubicin is highly active in the treatment of metastatic breast cancer (MBC). In an effort to improve patient convenience, we investigated a regimen alternating i.v. and oral vinorelbine in combination with epirubicin as first-line chemotherapy of patients with MBC. In all, 49 patients with MBC received, as first-line treatment, a combination regimen consisting of i.v. vinorelbine 25 mg m À2 plus epirubicin 90 mg m À2 given on day 1, and oral vinorelbine 60 mg m À2 on day 8 (or day 15 if neutrophils o1500 mm À3 ) every 3 weeks, in an open-label, multicentre phase II study. Treatment was to be repeated for a maximum of six cycles. The study population had a median age of 55 years, half of the patients had received prior adjuvant chemotherapy and 86% presented a visceral involvement. In all, 25 responses were documented and validated by an independent panel review, yielding response rates of 51% (95% CI: 36 -66) in the 49 enrolled patients and 54.5% (95% CI: 39 -70) in the 44 evaluable patients. Median durations of progression-free survival and survival were 8 and 20 months, respectively. Neutropenia was the main dose-limiting toxicity, but complications were uncommon, four patients having experienced febrile neutropenia and six having developed neutropenic infection. Other frequently reported adverse events included stomatitis, nausea and vomiting, which were rarely severe. No toxic death was reported. Among patients who received six cycles, global score of quality of life remained stable. This regimen alternating oral and i.v. vinorelbine in combination with epirubicin is effective and safe. Oral vinorelbine on day 8 offers greater convenience to the patient, and decreases the need for i.v. injection and reduces time spent in hospital. Therefore, oral vinorelbine is a convenient alternative to the i.v. form in combination regimens commonly used to treat MBC.

show abstract

mentioning

confidence: 92%

Vinorelbine alternating oral and intravenous plus epirubicin in first-line therapy of metastatic breast cancer: results of a multicentre phase II study

Serin

Verrill²,

Jones

et al. 2005

Br J Cancer

View full text Add to dashboard Cite

show abstract

“…Several phase II studies of singleagent VRL as first-line treatment in advanced breast cancer have been conducted (Canobbio et al, 1989;Lluch et al. 1992;Fumoleou et al, 1993;Romero et al, 1994;Twelves et al, 1994), with response rates ranging from 41% to 60%, good tolerance, minor neurotoxicity and rapidly reversible leucopenia. Furthermore, synergy and good tolerance have been observed when vinorelbine is used in combination with platinum compounds (Cros.…”

mentioning

confidence: 99%

A phase II study of carboplatin and vinorelbine as second-line treatment for advanced breast cancer

et al. 1995

View full text Add to dashboard Cite

Slmnerap Forty-one patients with advanced breast cancer were gven carboplatin and vinorelbine as secondline therapy. Overall objective response rate was 46% (95% confidence interval 26-56%). Myelotoxcicity was the most frequently observed toxic effect; grade III-IV leucopenia occurred in 46% of the patients. Our regimen is active as second-line chemotherapy for advanced breast cancer and warrants further evaluation.

show abstract

“…vinorelbine given intravenously at 30 mg/m 2 /week showed an objective response rate of 40 -60% [3][4][5][6][7][8][9][10] and as salvage therapy, 16 -64%. [11][12][13][14][15][16] The dose-limiting toxic effect of weekly vinorelbine is neutropenia.…”

mentioning

confidence: 99%

Phase I study of vinorelbine and paclitaxel by 3‐hour simultaneous infusion with and without granulocyte colony‐stimulating factor support in metastatic breast carcinoma

Ibrahim

Buzdar

Valero

et al. 2001

Cancer

View full text Add to dashboard Cite

Vinorelbine as first-line chemotherapy for metastatic breast carcinoma.

Abstract: VNB is an active drug against metastatic breast cancer with moderate toxicity, which justifies further evaluation in association with other agents.

Cited by 179 publications

References 6 publications

Vinorelbine alternating oral and intravenous plus epirubicin in first-line therapy of metastatic breast cancer: results of a multicentre phase II study

Vinorelbine alternating oral and intravenous plus epirubicin in first-line therapy of metastatic breast cancer: results of a multicentre phase II study

A phase II study of carboplatin and vinorelbine as second-line treatment for advanced breast cancer

Phase I study of vinorelbine and paclitaxel by 3‐hour simultaneous infusion with and without granulocyte colony‐stimulating factor support in metastatic breast carcinoma

Contact Info

Product

Resources

About